Monopar Therapeutics (NASDAQ:MNPR) Coverage Initiated by Analysts at HC Wainwright

Key Points

• Monopar Therapeutics has received a "buy" rating from HC Wainwright, with a target price of $70.00, indicating a potential upside of 130.11% from its previous closing price.
• The company's stock has experienced significant volatility, with a fifty-two week range from $2.25 to $54.30, and a market capitalization of approximately $187.69 million.
• Insider trading activity included the sale of 42,504 shares by executives, which represents a reduction in their ownership stakes, highlighting potential concerns over insider confidence.

HC Wainwright initiated coverage on shares of Monopar Therapeutics (NASDAQ:MNPR - Free Report) in a research report report published on Tuesday morning, Marketbeat reports. The firm issued a buy rating and a $70.00 price objective on the stock. HC Wainwright also issued estimates for Monopar Therapeutics' Q3 2025 earnings at ($0.51) EPS, Q4 2025 earnings at ($0.54) EPS, FY2025 earnings at ($1.78) EPS, Q1 2026 earnings at ($0.58) EPS, Q2 2026 earnings at ($0.62) EPS, Q3 2026 earnings at ($0.47) EPS, Q4 2026 earnings at ($0.50) EPS, FY2026 earnings at ($2.12) EPS, FY2027 earnings at ($1.34) EPS, FY2028 earnings at ($0.74) EPS and FY2029 earnings at ($0.35) EPS.

A number of other research firms also recently commented on MNPR. Cantor Fitzgerald assumed coverage on shares of Monopar Therapeutics in a research note on Monday, July 7th. They set an "overweight" rating and a $74.00 price objective on the stock. Wall Street Zen upgraded shares of Monopar Therapeutics from a "sell" rating to a "hold" rating in a research note on Thursday, May 22nd. Finally, Chardan Capital reiterated a "buy" rating and set a $60.00 price objective on shares of Monopar Therapeutics in a research note on Wednesday, August 13th. Five equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $66.00.

Monopar Therapeutics Stock Performance

Shares of MNPR stock traded down $1.91 on Tuesday, hitting $34.15. The stock had a trading volume of 15,130 shares, compared to its average volume of 34,835. The firm has a market capitalization of $210.71 million, a price-to-earnings ratio of -10.26 and a beta of 1.05. The stock's 50 day moving average is $37.89 and its 200-day moving average is $36.82. Monopar Therapeutics has a 52-week low of $2.25 and a 52-week high of $54.30.

Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) last announced its earnings results on Tuesday, August 12th. The company reported ($0.35) earnings per share for the quarter, beating the consensus estimate of ($0.47) by $0.12. Equities analysts expect that Monopar Therapeutics will post -1.65 earnings per share for the current year.

Insiders Place Their Bets

In other Monopar Therapeutics news, CEO Chandler Robinson sold 16,800 shares of the stock in a transaction on Monday, July 14th. The shares were sold at an average price of $40.00, for a total transaction of $672,000.00. Following the sale, the chief executive officer directly owned 73,472 shares of the company's stock, valued at approximately $2,938,880. This represents a 18.61% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Kim R. Tsuchimoto sold 8,904 shares of the stock in a transaction on Monday, July 14th. The stock was sold at an average price of $40.00, for a total transaction of $356,160.00. Following the sale, the director directly owned 11,486 shares in the company, valued at $459,440. This trade represents a 43.67% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 42,504 shares of company stock valued at $1,700,160. Company insiders own 20.50% of the company's stock.

Institutional Trading of Monopar Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of MNPR. Janus Henderson Group PLC acquired a new stake in shares of Monopar Therapeutics during the fourth quarter worth $23,435,000. RA Capital Management L.P. acquired a new stake in shares of Monopar Therapeutics in the 4th quarter worth about $11,247,000. Point72 Asset Management L.P. acquired a new stake in shares of Monopar Therapeutics in the 4th quarter worth about $3,694,000. Affinity Asset Advisors LLC acquired a new stake in shares of Monopar Therapeutics in the 1st quarter worth about $2,257,000. Finally, Geode Capital Management LLC increased its holdings in shares of Monopar Therapeutics by 99.7% in the 2nd quarter. Geode Capital Management LLC now owns 96,919 shares of the company's stock worth $3,468,000 after acquiring an additional 48,379 shares during the period. 1.83% of the stock is owned by institutional investors and hedge funds.

Monopar Therapeutics Company Profile

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.